Dividends & Buybacks ·
Lakefront Biotherapeutics completes €2.85M share repurchase program
GLPGFLakefront Biotherapeutics NV
Lakefront Biotherapeutics NV completed its share repurchase program announced on June 9, 2026, by purchasing 107,804 shares between October 12 and October 16, 2026. The company spent a total of €2,854,365.69 at an average price of €26.48 per share across multiple European exchanges. As of market close on October 16, Lakefront holds 1,985,157 of its own ordinary shares. The filing discloses the final execution details of this discretionary mandate to an independent financial intermediary. Lakefront Biotherapeutics is a clinical-stage biotechnology company developing immunology and inflammation treatments.